Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • PMN310 | Amyloid-Beta
    • PMN267 | TDP-43
    • PMN442 | Alpha-Synuclein
    • Vaccines
    • Posters & Publications
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Results
  • Stock Data
    • NASDAQ: PMN
    • Analyst Coverage
  • SEDAR
  • SEC Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents

  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Aug 11, 2017

ProMIS Neurosciences Announces Second Quarter 2017 Results

Jul 5, 2017

ProMIS Neurosciences to Present Preclinical Data from Alzheimer's Disease Program at AAIC 2017

Jun 6, 2017

ProMIS™ Neurosciences Appoints William C. Mobley to Scientific Advisory Board

May 31, 2017

ProMIS Neurosciences Identifies Novel Therapeutic Epitope Target for ALS and Dementia

May 25, 2017

Prion 2017: Deciphering Neurodegenerative Disorders - 23-26 May 2017 Edinburgh

May 24, 2017

ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer's Disease

  • arrow_back
  • 1…
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • Email Alerts
  • Contacts
Facebook Linkedin Spotify Twitter
©2025 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy